Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

$4,450 $4,650

**GROSS MARGIN approx. 77%

**SG&A approx. 27%

**R&D approx. 17%

Net Interest / Other approx. 60

TAX RATE - GAAP approx. 30%

*TAX RATE - NON-GAAP approx. 31%

GENZ GAAP EPS approx. $2.65

AMORTIZATION approx. $0.55

FAS123 EXPENSE approx. $0.60

CONTINGENT CONVERTIBLE DEBT approx. $0.10

**GENZ NON-GAAP EPS $3.90

***WTD AVERAGE SHARES O/S approx. 274

CAPITAL EXPENDITURES approx. $500

This financial guidance, which is provided as part of a press release

dated April 21, 2008, is subject to all of the qualifications and

limitations described therein. Actual results may differ from these

forward-looking statements due to the numerous factors described in the

press release.

* Non-GAAP tax rate excludes the impact of amortization, one-time events,

FAS123R expense and EITF 04-8.

**Non-GAAP excludes the impact of amortization, one-time events, FAS123R

expense and EITF 04-8.

***WTD Average Shares Outstanding excludes the impact of EITF 04-8.


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... BALTIMORE , March 4, 2015 The ... of its 2015 Fellows in the Emerging Leaders in ... fostering future leaders in the field of biosecurity, UPMC ... biosecurity from a wide array of backgrounds, including biological ... private sector. "With the vision and ...
(Date:3/4/2015)... , March 4, 2015 /CNW/ - Resverlogix Corp. ... has completed a collaborative research program with ...  Using Fast Collective Evolution Technology (FACET), Emerald ... all measurements obtained from each of 798 ... 2 clinical trials ASSERT, SUSTAIN and ASSURE. ...
(Date:3/4/2015)... March 4, 2015 Vegalab announced the acquisition ... of last year. As part of the acquisition, Ecowin ... continuing his role as CEO for the company,s ... S.A., will work alongside Koo and oversee developments at ... http://photos.prnewswire.com/prnh/20150303/179218 Koo founded Ecowin in ...
(Date:3/3/2015)... /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), ... that target the underlying mechanisms of cancer, today reported ... December 31, 2014. Effective July 17, 2014, ... 31 to December 31. As a result of that ... the quarter and the seven months ended December 31, ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... 2011 Answering the need for global, site-focused enrollment ... patient enrollment industry, announces the expansion of its services ... local, site-centric level. "The extension of our ... us to assist sponsors with their global patient enrollment ...
... 2011 Techne Corporation (NASDAQ: TECH ) announced ... dividend of $0.27 per share for the quarter ended March ... 2011 to all common shareholders of record on May 13, ... of Directors on a quarterly basis. Techne Corporation ...
... May 2, 2011 VIVUS, Inc. (Nasdaq: ... of novel therapeutic products, today reported its financial results for the ... Quarter ResultsFor the quarter ended March 31, 2011, VIVUS reported a ... to a net loss of $18.8 million or $0.23 per share ...
Cached Biology Technology:Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World 2VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5
(Date:2/19/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ) ... Electro-Optical / Infrared Systems Market by Type, by ... to 2020" report to their offering. ... expected to reach $16.35 billion by 2020, to ... report segments the military electro-optical/infrared systems market on ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
(Date:2/10/2015)... Mass., Feb. 10, 2015  Alere Inc. (NYSE: ... its financial results for the quarter ended December ... Officer and President of Alere said, "We made ... Alere as the global leader in rapid diagnostics ... the Alere Health divestiture in early January enabled ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
... available in German . FRANKFURT. A newly synthesized ... never fold into its correct three dimensional structure if it ... In case of membrane proteins chaperones do not only pre-vent ... aid in membrane insertion. The underlying molecular mechanism of how ...
... the world,s "missing" or undiscovered species live in regions ... a new study published this week in the journal ... The study,s findings suggest recent conservation efforts have ... conservation priorities, its team of international authors say. But, ...
... University School of Medicine (BUSM) and Boston Medical Center (BMC) ... of adipose, or fat, tissue is a significant contributing ... obese individuals. The study, which is a special feature on ... College of Cardiology, provides compelling evidence that the answer ...
Cached Biology News:A chaperone system guides tail-anchored membrane proteins to their destined membrane 2Most of world's 'missing species' live in known hotspots 2Study shows answers for treating obesity-related diseases may reside in fat tissue 2
... been designed and created in order to ... genotyping analysis tool. We incorporated the suggestions ... the software. Their main requirements were ease- ... acquisition cost. GeneMarker can perform analysis ...
... The ProLink Express is the first fully ... delivery and transfer operations with complete data ... initial bacterial colony picking through final protein ... is capable of delivering a plate to ...
... phase extraction through columns is a well-known ... applications. Typical applications are in DNA/RNA extraction ... or compound purification in chemical or analytical ... on the Genesis series instruments for smaller ...
... is a multi-functional program that ... from a sequence file for ... sequencing, site-directed mutagenesis, and various ... temperature and secondary structure of ...
Biology Products: